Changes in interstitial collagen metabolism during acute myocardial infarction treated with streptokinase or tissue plasminogen activator

American Heart Journal

Volumn 131, Issue 1, 1996, Pages 7-13

  Peuhkurinen, Keijo ^a,b   Risteli, Leila ^a   Jounela, Antti ^a   Risteli, Juha ^a  

^a UNIVERSITY OF OULU   (Finland)

^b OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; FIBRINOLYTIC AGENT; HEPARIN; PROCOLLAGEN; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CARBOXY TERMINAL SEQUENCE; CLINICAL ARTICLE; CLINICAL PROTOCOL; COLLAGEN METABOLISM; DISEASE COURSE; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION;

EID: 0030050160     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(96)90044-7     Document Type: Article

References (33)

1. DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980;303:897-902.
2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-60.
3. Gruppo Italiano per lo Studio della Streptochinasi nell Infarto Miocardico (GISSI). GISSI-2: a factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12490 patients with acute myocardial infarction. Lancet 1990;336:65-71.
4. ISIS-3: a randomized comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41299 cases of suspected acute myocardial infarction. Lancet 1992;339:1-18.
5. The GUSTO Investigators: an international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82.
6. Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator: role of fibrin. J Biol Chem 1982;257:2912-9.
7. Lee, CD, Mann KG. Activation/inactivation of human factor V by plasmin. Blood 1989;73:185-90.
8. Hamilton KK, Fretto LJ, Giersa DS, McKee PA. Effects of plasmin on von Willebrand factor multimers: degradation in vitro and stimulation of release in vivo. J Clin Invest 1985;76:261-70.
9. Lawler J, Slayter H. The release of heparin binding peptides from platelet thrombospondin by proteolytic action of thrombin, plasmin and trypsin. Thromb Res 1981;22:267-79.
10. Liotta LA, Goldfarb RH, Brundage R, Siegal GP, Terranova V, Garbisa S. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 1981;41:4629-36.
11. Eechout Y, Vaes G. Further studies on the activation of procollagenase, the latent precursor of bone collagenase: effects of lysosomal cathepsin B, plasmin, and kallikrein, and spontaneous activation. Biochem J 1977;166:21-31.
12. Salo T, Liotta LA, Keski-Oja J, Turpeenniemi-Hujanen T, Tryggvason K. Secretion of basement membrane collagen degrading enzyme and plasminogen activator by transformed cells-role in metastasis. Int J Cancer 1982;30:669-73.
13. Peuhkurinen KJ, Risteli L, Melkko JT, Linnaluoto M, Jounela A, Risteli J. Thrombolytic therapy with streptokinase stimulates collagen breakdown. Circulation 1991;83:1969-75.
14. Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, Bell WR, Knatterud G, Robertson TL, Terrin ML and TIMI investigators. Thrombolysis in myocardial infarction (TIMI) trial-phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988;11:1-11.
15. Honan MB, Harrell FE, Reimer KA, Califf RM, Mark DB, Pryor DB, Hlatky MA. Cardiac rupture, mortality and the timing of thrombolytic therapy: a meta-analysis. J Am Coll Cardiol 1990;16:359-67.
16. Whittaker P, Boughner DR, Kloner RA. Role of collagen in acute myocardial infarct expansion. Circulation 1991;84:2123-34.
17. Risteli J, Niemi S, Trivedi P, Mowat AP, Risteli L. Rapid equilibrium radioimmunoassay for the aminoterminal propeptide of human type III procollagen. Clin Chem 1988;34:715-8.
18. Melkko J, Niemi S, Risteli L, Risteli J. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 1990;36:1328-32.
19. Matthews JNS, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. Br Med J 1990;300:230-5.
20. Fleischmajer R, Perlish JS, Timpl R. Collagen fibrillogenesis in human skin. Ann N Y Acad Sci 1985;460:246-57.
21. Risteli J, Risteli L. Markers of collagen assembly and turnover. In: Lindh E, Thorell JI, editors. Clinical impact of bone and connective tissue markers. New York: Academic Press, 1989:201-9.
22. Verstraete M, Bernard R, Bory M, Brouer RW, Collen D, deBono DP Erbel R, Huhmann W, Lennane J. Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Co-operative Study Group for Recombinant Tissue-type Plasminogen Activator. Lancet 1985;1:842-7.
23. Chesebro JH, Badimon L, Fuster V. New approaches to treatment of myocardial infarction. Am J Cardiol 1990;65:9C-12C.
24. Weitz JI, Hudoba M, Massel J, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin-III independent inhibitors. J Clin Invest 1990;86:385-91.
25. Marder VJ. Relevance of changes in blood fibrinolytic and coagulation parameters during thrombolytic therapy. Am J Med 1987;83(suppl(I-Ia): 15-9.
26. Maggioni AP, Franzosi MG, Santorio E, White H, van de Werf F, Tognoni G. The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. N Engl J Med 1992;327:1-6.
27. Jensen LT, Horslev-Petersen K, Toft P, Bentsen KD, Grande P, Simonsen EE, Lorenzen I. Serum aminoterminal type III procollagen peptide reflects repair after acute myocardial infarction. Circulation 1990;81:52-7.
28. Haukipuro K, Risteli L, Kairaluoma MI, Risteli J. Aminoterminal propeptide of type III procollagen in serum during wound healing in human beings. Surgery 1990;107:381-8.
29. Oikarinen AI, Uitto J, Oikarinen J. Glucocorticoid action on connective tissue: from molecular mechanisms to clinical practice. Med Biol 1986;64:221-30.
30. Ceremuzynski L. Hormonal and metabolic reactions evoked by acute myocardial infarction. Circ Res 1981:48:767-75.
31. Breshanan GF, Roberts R, Shell WE, Ross J Jr, Sobel BE. Deleterious effects due to haemorrhage after myocardial reperfusion. Am J Cardiol 1974;33:82-6.
32. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction: experimental observations and clinical implications. Circulation 1990;81:1161-72.
33. Fibrinolytic Therapy Trialists (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results of all randomised trials of more than 1000 patients. Lancet 1994; 343:311-22.